# An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors

> **NCT06094556** · PHASE1 · RECRUITING · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 240 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** SHR-1826

## Key facts

- **NCT ID:** NCT06094556
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-25
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-07-31
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2025-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06094556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06094556, "An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06094556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*